ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0719

Anti-adalimumab Antibodies Detection Using a Novel Peptide-based Assay in a Cohort of Pediatric Patients with Chronic Rheumatic Disorders: A Pilot Study

Edoardo Marrani1, Hendrik Rusche2, Francesco Terzani3, Elisa Peroni4, Feliciana Real-Fernandez5, Olivier Monasson4, Roberta Ponti6, Gabriele Simonini7, Anna Maria Papini3 and Paolo Rovero5, 1University of Florence, Firenze, Italy, 2Peptlab@CY and Laboratory of Chemical Biology, Cergy-Paris University, Cergy-Pontoise,, France, 3PeptLab, Dep. Chemistry, University of Florence, Sesto FIorentino, Italy, 4Peptlab@CY and Laboratory of Chemical Biology, Cergy-Paris University, cergy-pontoise, France, 5PeptLab, Dep. NEUROFARBA, University of Florence, Firenze, Italy, 6Pediatric Department, University of Udine, udine, Italy, 7Rheumatology Unit, Meyer Children's University Hospital, Florence; NEUROFARBA Department, University of Florence, Italy, Florence, Italy

Meeting: ACR Convergence 2020

Keywords: Anti-TNF Drugs, biologic response modifiers, Biomarkers, Pediatric rheumatology, TNF-blocking Antibody

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Saturday, November 7, 2020

Session Title: Pediatric Rheumatology – Clinical Poster II: JIA

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Immunogenicity and development of anti-drug antibodies have been associated with treatment failure and adverse events during biologic treatment. Anti-drug antibodies (ADAs) have been reported in 21% of Juvenile Idiopathic Arthritis patients treated with Adalimumab. However, their role in reducing adalimumab efficacy is still debated due to conflicting results. No study has been directed toward identification of neutralizing ADAs in paediatric rheumatic disorders. 

Aim of our study was to detect ADAs, along with their clinical relevance, using a new theranostic peptide-base assay in a cohort of children with inflammatory chronic diseases on Adalimumab treatment.

Methods: ix candidate Adalimumab derived peptide antigens (HC-CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR 2, LC CDR3) have been developed and optimized to be tested. Their performance has been compared with commercial ELISA kit and a SPR-based optical assay (Biacore®). Assays have been performed in sera of a cohort of children receiving Adalimumab due to an inflammatory chronic disease. Mean age, disease duration, concomitant treatment with methotrexate (MTX), ANA positivity, disease activity parameters and scores at the time of ADA determination have been recorded. Chi-square, and Fisher exact test were used to compare data. Pearson’s and Spearman’s correlation tests were used to determine correlation coefficients for entered variables.

Results: Eighteen (14 F, median age 12.6, range 3.8-16, yrs) patients were enrolled: 16 affected by Juvenile Idiopathic Arthritis, 7 of whom complicated by JIA -associated chronic uveitis, and 2 patients affected by chronic idiopathic uveitis. Peptide assay revealed ADAs in 8 children, Biacore in 6, commercial Elisa in 5. Of note, we found total concordance among the 3 tests just in 2 patients. No significant correlation has been proven among the 3 ADA determinations. Biacore and ELISA determination showed significant concordance (rs: 0.72, p< 0.006). The presence of HC CDR3 and LC CDR 3 resulted significantly correlated with disease activity (rs: 0.57, p< 0.05), and, inversely, with disease remission on treatment (rs= -0.523, p< 0.05). No patient experienced severe adverse events and no correlation with ADAs has been revealed.

Conclusion: In chronic rheumatic disorders, novel reliable methods are urgently required to guide clinical decision and support decisions about switching within or between drugs in refractory children. The 3 different methods, since based on different antigenic probes, detect different antibody populations. The present peptide-based assays might contribute to identify neutralizing ADAs in patients treated with Adalimumab. Further validation in larger cohort is required.


Disclosure: E. Marrani, None; H. Rusche, None; F. Terzani, None; E. Peroni, None; F. Real-Fernandez, None; O. Monasson, None; R. Ponti, None; G. Simonini, None; A. Papini, Espikem srl, 6; P. Rovero, Espikem srl, 6.

To cite this abstract in AMA style:

Marrani E, Rusche H, Terzani F, Peroni E, Real-Fernandez F, Monasson O, Ponti R, Simonini G, Papini A, Rovero P. Anti-adalimumab Antibodies Detection Using a Novel Peptide-based Assay in a Cohort of Pediatric Patients with Chronic Rheumatic Disorders: A Pilot Study [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/anti-adalimumab-antibodies-detection-using-a-novel-peptide-based-assay-in-a-cohort-of-pediatric-patients-with-chronic-rheumatic-disorders-a-pilot-study/. Accessed January 22, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-adalimumab-antibodies-detection-using-a-novel-peptide-based-assay-in-a-cohort-of-pediatric-patients-with-chronic-rheumatic-disorders-a-pilot-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.